Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 51.48

+0.7%

10:47 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: nigel bates who wrote (3289)	4/2/2001 11:41:40 AM
From: scaram(o)uche	Read Replies (1) of 52153

>> CRGN/(and eg)ABGX would be a pretty nice fit. << Too many eggs in the antibody basket, IMO. MLNM paid a huge premium for LKST, but look at what it did for the business plan, extending forward. With CRGN and ABGX, if anti-IL-8 doesn't pan out, you would have a bigger cash- and future-rich biotech. I feel that CRGN should focus on finding a LKST-like op. TTP fit with anyone?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next